5G3
vs
FTSE Straits Times Singapore

Over the past 5 years, 5G3 has outperformed FTSE Straits Times Singapore, delivering a return of 3% compared to the FTSE Straits Times Singapore's 1% growth.

Stocks Performance
5G3 vs FTSE Straits Times Singapore

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
5G3 vs FTSE Straits Times Singapore

Performance Comparison
5G3 vs FTSE Straits Times Singapore

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
5G3
Talkmed Group Ltd
-1%
-2%
13%
20%
3%
33%
64%
FTSE Straits Times Singapore
Market Index
N/A
N/A
N/A
N/A
1%
-2%
24%

Talkmed Group Ltd
Glance View

Market Cap
590.4m SGD
Industry
Health Care

TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).

5G3 Intrinsic Value
0.302 SGD
Overvaluation 32%
Intrinsic Value
Price
T

See Also

Back to Top